Breathe in hope: new mRNA vaccine targets lung tumors
NCT ID NCT06928922
First seen Jan 16, 2026 · Last updated May 23, 2026 · Updated 16 times
Summary
This early-phase study tests an inhaled mRNA vaccine called BMD006 for people with advanced lung cancer or solid tumors that have spread to the lungs. The vaccine is designed to train the immune system to attack tumor-related proteins. About 83 participants who have exhausted standard treatments will receive the vaccine alone or with an immunotherapy drug, to check safety and see if tumors shrink.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.